Pfizer closes Ferrosan Consumer Health deal
This article was originally published in Scrip
Executive Summary
Pfizer says it has closed its purchase of the consumer healthcare firm, Ferrosan. The US firm announced its intention to buy the Danish company earlier this year (scripintelligence.com, 7 February 2011). Ferrosan's business includes dietary supplements and lifestyle products and should broaden Pfizer's own portfolio. "Ferrosan Consumer Health's innovative products and geographic footprint are a strong fit for our business," said Paul Sturman, president of Pfizer Consumer Healthcare. The financial details of the deal have not been disclosed.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.